Enodia Therapeutics Names Henrik Torp Nielsen CFO

The biotechnology company, developing protein-degradation therapies, has appointed a finance executive with nearly two decades of biopharma experience.

Updated on Nov. 18, 2026 in Biotech

Enodia Therapeutics Names Henrik Torp Nielsen CFO

Enodia Therapeutics appointed Henrik Torp Nielsen as Chief Financial Officer. Nielsen brings nearly two decades of experience in biopharma finance and operations to the Paris-dateline company.

Why it matters

Enodia is developing small-molecule therapies that selectively degrade disease-driving proteins before they mature, and a finance leader with operational depth supports the company as it advances its pipeline. The move signals the company's continued build-out of its leadership team around its proprietary Sec61 platform.

Enodia's pipeline rests on its proprietary Sec61 platform, which underpins its small-molecule approach to protein degradation at the point of synthesis. The announcement does not specify technical performance metrics or clinical milestones for the platform.

The players

Enodia Therapeutics

Enodia Therapeutics is a biotechnology company developing small-molecule therapies that target protein degradation at the point of synthesis, built by Argobio and rooted in Institut Pasteur research.

Henrik Torp Nielsen

Henrik Torp Nielsen is a finance and operations executive with nearly two decades of experience in biopharma, newly appointed as Enodia's Chief Financial Officer.

The details

Enodia Therapeutics, rooted in research from the Institut Pasteur and built by Argobio, has an initial pipeline focus on inflammatory and autoimmune diseases with additional opportunities in oncology. The company announced Nielsen's appointment in a release datelined Paris on October 29, 2026.

Timeline

  1. October 29, 2026: Enodia announces the appointment of Henrik Torp Nielsen as Chief Financial Officer from Paris.

Tech Race

Enodia's Sec61-based approach traces to research from the Institut Pasteur, placing the company within the translation of academic protein-biology work into commercial drug development. Its focus on selectively degrading disease-driving proteins before they mature distinguishes it from conventional inhibitor-based strategies.

For patients with inflammatory, autoimmune, or cancer conditions, the company's pipeline represents a potential future treatment option, though no timelines for clinical availability are disclosed. The leadership change does not by itself alter any current therapy, prescription, or access route.

The takeaway

Leadership appointments at early-stage biotechnology companies often signal preparation for financing and pipeline progression rather than immediate clinical change. Readers tracking the sector can watch for subsequent funding or clinical updates from the company.

Further reading

Explore more Biotech coverage for context on companies advancing protein-degradation and other drug-development platforms.

Source note: This article includes information reported by Paris Guardian.